Traditional therapies: Glucocorticoids, azathioprine, methotrexate, hydroxyurea;Traditionelle therapien: Glukokortikoide, azathioprin, methotrexat, hydroxyharnstoff

H+G Zeitschrift fur Hautkrankheiten

Volumn 77, Issue 12, 2002, Pages 624-632

  Belgi, G ^a   Friedmann, P S ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

Azathioprine; Glucocorticoids; Hydroxyurea; Immunomodulators; Mechanisms; Methotrexate

Indexed keywords

ADENOSINE; ANNEXIN; AZATHIOPRINE; CYTOKINE; DNA; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HYDROXYUREA; INTERLEUKIN 6; INTERLEUKIN 8; METHOTREXATE; PROSTAGLANDIN; PROTEIN KINASE; PURINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

B LYMPHOCYTE; BIOSYNTHESIS; CELL PROLIFERATION; CHEMOTAXIS; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INFLAMMATION; MONOCYTE; MONONUCLEAR CELL; NEUTROPHIL; PHOSPHORYLATION; PROMOTER REGION; RECEPTOR BINDING; REVIEW; T LYMPHOCYTE;

EID: 0036919114     PISSN: 03010481     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1439-0353.2002.02628.x     Document Type: Review

References (85)

1. Almawi, W.Y., O.K. Melemedjian (2002): Negative regulation of nuclear factor-kappaB activation and function by glucocorticoids. J Mol Endocrinol, 28, 69-78.
2. Beato, M., J. Klug (2000): Steroid hormone receptors: An update. Hum Reprod Update, 6, 225-236.
3. Beato, M., S. Chavez, M. Truss, (1996): Transcriptional regulation by steroid hormones. Steroids, 61, 240-251.
4. Croxtall, J.D., P.T. van Hal, Q. Choudhury, D.W. Gilroy, R.J. Flower (2002): Different glucocorticoids vary in their genomic and non-genomic mechanism of action in A549 cells. Br J Pharmacol, 135, 511-519.
5. Croxtall, J.D., R.J. Flower, (1992): Lipocortin 1 mediates dexamethasone-induced growth arrest of the A549 lung adenocarcinoma cell line. Proc Natl Acad Sci USA, 89, 3571-3575,
6. Almawi, W.Y., O.K. Melemedjian (2002): Molecular mechanisms of glucocorticoid antiproliferative effects: Antagonism of transcription factor activity by glucocorticoid receptor. J Leukoc Biol, 71, 9-15.
7. Croxtall, J.D., Q. Choudhury, R.J. Flower (2000): Glucocorticoids act within minutes to inhibit recruitment of signalling factors to activated EGF receptors through a receptor-dependent, transcription-independent mechanism. Br J Pharmacol, 130, 289-298.
8. Taylor, D. D., J.G. Philip, C.D. John et al (2000): Annexin 1 (lipocortin 1) mediates the glucocorticoid inhibition of cyclic adenosine 3′,5′-monophosphate-stimulated prolactin secretion. Endocrinology, 141, 2209-2219,
9. Strausbaugh, H.J., S.D. Rosen (2001): A potential role for annexin 1 as a physiologic mediator of glucocorticoid-induced 1-selectin shedding from myeloid cells. J Immunol, 166, 6294-6300.
10. Buttgereit, F., M. Wehling M, G.R. Burmester (1998): A new hypothesis of modular glucocorticoid actions: Steroid treatment of rheumatic diseases revisited. Arthritis Rheum, 41, 761-767.
11. Lennard, L., C.A. Rees, J.S. Lilleyman, J.L. Maddocks (1983): Childhood leukaemia, a relationship between intracellular 6-mercaptopurine metabolites and neutropenia. Br J Clin Pharmacol, 16, 359-363.
12. Chocair, P.R., J.A. Duley, H.A. Simmonds, J.S. Cameron (1992): The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients. Transplantation, 53, 1051-1056.
13. Page, A.R. (1964): Inhibition of lymphocyte response to inflammation with anti metabolites. Am J Pharm, 45, 1029-1039.
14. Hurd, E.R., M. Ziff (1968): Studies on the anti-inflammatory action of 6-mercaptopurine. J Exp Med, 1068, 785-800.
15. Hersh, E.M., V.J. Wong, E.J. Freireich (1966): Inhibition of the local inflammatory response in man by antimetabolites, Blood, 27, 38-48.
16. Homo-Deiarche, F., J.F. Bach, M. Dardenne M. (1988): In vitro inhibition of prostagiandin production by azathioprine and 6-mercaptopurine. Prostaglandins, 35, 479-491.
17. Levy, J., E.V. Barnett, N.S. MacDonald, J.R. Klinenberg, C.M. Pearson (1972): The effect of azathioprine on gammaglobulin synthesis in man. J Clin Invest, 51, 2233-2238.
18. Dimitriu, A., A.S. Fauci (1979): Differential sensitivity of humanlymphocyte subpopulations to azathioprine. Transplant Proc, 11, 878-881.
19. Levin, R.H., M. Landy, E. Frie (1964): The effects of 6-MP on immune responses in man. New Eng J Med, 271, 16.
20. Campbell, A.C., J.M. Skinner, I.C. MacLennan et al. (1976): Immunosuppression in the treatment of inflammatory bowel disease. II. The effects of azathioprine on lymphoid cell populations in a double blind trial in ulcerative colitis. Clin Exp Immunol, 24, 249-258.
21. Dodd, H.J., F.M. Tatnall, I. Sarkany (1985): Fast atrial fibrillation induced by treatment of psoriasis with azathioprine. Br Med J (Clin Res Ed), 291, 706.
22. Spencer, E. S., H.K. Andersen (1979): Viral infections in renal allograft recipients treated with long-term immunosuppression. Br Med J, 2, 829-830.
23. Paterson, W.D., B.R. Allen, G.W. Beveridge (1973): Norwegian scabies during immunosuppressive therapy. Br Med J, 4, 211-212.
24. Bottomley, W.W., G. Ford, W.J. Cunliffe, J.A. Cotterill (1985): Aggressive squamous cell carcinomas developing in patients receiving longterm azathioprine. Br J Dermatol, 133, 460-462.
25. Wolverton, S.E. (1992): Monitoring for adverse effects from systemic drugs used in dermatology. J Am Acad Dermatol, 26, 661-679.
26. Jones, J.J., J. Ashworth (1993): Azathioprine-induced shock in dermatology patients. J Am Acad Dermatol, 29, 795-796.
27. Compton, M.R., D.L. Crosby (1996): Rhabdomyolysis associated with azathioprine hypersensitivity syndrome. Arch Dermatol, 132, 1254-1255.
28. Blanco, R., V.M. Martinez-Taboada, M.A. Gonzalez-Gay et al. (1996): Acute febrile toxic reaction in patients with refractory rheumatoid arthritis who are receiving combined therapy with methotrexate and azathioprine. Arthritis Rheum, 39, 1016-1020.
29. Parnham, A.P., I. Dittmer, P.W. Mathieson, A. Mclver, C. Dudley (1996): Acute allergic reactions associated with azathioprine, Lancet, 348, 542-543.
30. Lever, W.F., G. Schaumburg-Lever (1984): Treatment of pemphigus vulgaris. Results obtained in 84 patients between 1961 and 1982. Arch Dermatol, 120, 44-47.
31. Burton, J.L., M.W. Greaves (1974): Azathioprine for pemphigus and pemphigoid - A 4 year follow-up. Br J Dermatol, 91, 103-109.
32. Burton, J.L., R.M. Harman, R.D. Peachey, R.P. Warin (1978): A controlled trial of azathioprine in the treatment of pemphigoid [proceedings]. Br J Dermatol, 99, 14.
33. Leigh, I.M., J.L. Hawk (1984): Treatment of chronic actinic dermatitis with azathioprine. Br J Dermatol, 110, 691-695.
34. Younger, I.R., D.W. Harris, G.B. Colver (1991): Azathioprine in dermatology. J Am Acad Dermatol, 25, 281-286.
35. Ginzler, E., E. Sharon, H. Diamond, D. Kaplan D. (1975): Long-term maintenance therapy with azathioprine in systemic lupus erythematosus. Arthritis Rheum, 18, 27-34.
36. Tsokos, G.C., S.W, Caughman, J.H. Klippel (1985): Successful treatment of generalized discoid skin lesions with azathioprine. Its use in a patient with systemic lupus erythematosus. Arch Dermatol, 121, 1323-1325.
37. Ashinoff, R., V.P. Werth, A.G. Franks Jr. (1988): Resistant discoid lupus erythematosus of palms and soles: Successful treatment with azathioprine. J Am Acad Dermatol, 19, 961-965.
38. Du, V.A., D.D. Munro, J. Verbov (1974): Treatment of psoriasis with azathioprine. Br Med J, 1, 49-51.
39. Woolfson, H. (1987): Acne fuiminans with circulating immune complexes and leukaemoid reaction treated with steroids and azathioprine. Clin Exp Dermatol, 12, 463-466.
40. Bleyer, W.A. (1978): The clinical pharmacology of methotrexate: New applications of an old drug. Cancer, 41, 36-51.
41. Bannwarth, B., L. Labat, Y. Moride, T. Schaeverbeke (1994): Methotrexate in rheumatoid arthritis. An update. Drugs, 47, 25-50.
42. Olsen, E.A. (1991): The pharmacology of methotrexate. J Am Acad Dermatol, 25, 306-318.
43. Hitchings, G.H., J.J. Burchall (1965): Inhibition of folate biosynthesis and function as a basis for chemotherapy. Adv Enzymol Relat Areas Mol Biol, 27, 417-468.
44. Cronstein, B.N. (1996): Molecular therapeutics. Methotrexate and ist mechanism of action. Arthritis Rheum, 39, 1951-1960.
45. Dutz, J.P., V.C.: Ho (1998): Immunosuppressive agents in dermatology. An update. Dermatol Clin, 16, 235-251.
46. Mitchell, M.S., M.E. Wade, R.C. DeConti, J.R. Bertino, P. Calabresi (1969): Immunosuppressive effects of cytosine arabinoside and methotrexate in man. Ann Intern Med, 70, 535-547.
47. Glynn, J. Pea, (1963): Effects of methotrexate and melphalan on the survival of tumor and skin homografts. Nature, 198, 1003-1004.
48. Duhra, P. (1993): Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis. J Am Acad Dermatol, 28, 466-469.
49. Zachariae, H., H. Sogaard, L. Heickendorff (1996): Methotrexate induced liver cirrhosis. Clinical, histological and serological studies - A further 10-year follow-up. Dermatology, 192, 343-346.
50. Roenigk, H.H. Jr, R. Auerbach, H.I. Maibach, G.D. Weinstein (1988): Methotrexate in psoriasis: Revised guidelines. J Am Acad Dermatol, 19, 145-156.
51. Rothe, M.J., C. Grin-Jorgensen, W.H. Ramsey, J.M. Grant-Kels (1995): Monitoring patients taking methotrexate. J Am Acad Dermatol, 32, 680.
52. Petrazzuoli, M., M.J. Rothe, C. Grin-Jorgensen, W.H. Ramsey, J.M. Grant-Kels (1994): Monitoring patients taking methotrexate for hepatotoxicity. Does the standard of care match published guidelines? J Am Acad Dermatol, 31, 969-977.
53. Rubin, E., C.S. Lieber (1968): Alcohol-induced hepatic injury in nonalcoholic volunteers. N Engl J Med, 278, 869-876.
54. Stern, R.S., N. Laird (1994): The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy Follow-Up Study Cancer, 73, 2759-2764.
55. Moller, H. (1969): Reactivation of acute inflammation by methotrexate. J Invest Dermatol, 52, 437-441.
56. McDonald, C.J., J.R. Bertino (1969): Parenteral methotrexate in psoriasis. A report on the efficacy and toxicity of long-term intermittent treatment. Arch Dermatol, 100, 655-668.
57. Roenigk, H.H. Jr, H.I. Maibach, G.D. Weinstein GD. (1972): Use of methotrexate in psoriasis. Arch Dermatol, 105, 363-365.
58. Rees, R.B., J.H. Bennett, H.I. Maibach, H.L. Arnold (1967): Methotrexate for psoriasis. Arch Dermatol, 95, 2-11.
59. Thomsen, K. (1971): Pustulosis palmaris et plantaris treated with methotrexate. Acta Derm Venereol, 51, 397-400.
60. Lever, W.F., H.S. Goldberg (1969): Treatment of pemphigus vulgaris with methotrexate. Arch Dermatol, 100, 70-78.
61. Lever, W.F. (1972): Methotrexate and prednisone in pemphigus vulgaris. Therapeutic results obtained in 36 patients between 1961 and 1970. Arch Dermatol, 106, 491-497.
62. Peck, S.M., K.E. Osserman, A.J. Samuels, B.W. Berger, R.S. Osserman (1971): Studies in bullous diseases. Treatment of pemphigus vulgaris with immunosuppressives (steroids and methotrexate) and leucovorin calcium. Arch Dermatol, 103, 141-147.
63. Rivitti, E.A., M.E. Camargo, R.M. Castro, S.A. Sampaio (1973): Use of methotrexate to treat pemphigus foliaceus. Int J Dermatol, 12, 119-122.
64. Capizzi, R.L., J.R. Bertino (1971): Methotrexate therapy of Wegener's granulomatosis. Ann Intern Med, 74, 74-79.
65. Mendoza, C.B. Jr, W.H. Gerwig Jr, A.L. Watne (1970): Dermatofibrosarcoma protuberans with metastases treated with methotrexate. Am J Surg, 120, 119-121.
66. Dantzig, P.I. (1974): Immunosuppressive and cytotoxic drugs in dermatology. Arch Dermatol, 110, 393-406.
67. Yarbro, J.W., B.J. Kennedy, C.P. Barnum (1965): Hydroxyurea inhibition of DNA synthesis in ascites tumor. Proc Natl Acad Sci USA, 53, 1033-1035.
68. Yarbro, J.W. (1992): Mechanism of action of hydroxyurea. Semin Oncol, 19, 1-10.
69. Yarbro, J.W. (1969): Hydroxyurea in the treatment of refractory psoriasis. Lancet, 2, 846-847.
70. Yarbro, J.W.,U.W. Leavell (1969): Hydroxyurea. A new agent for the management of refractory psoriasis. J Ky Med Assoc, 67, 899-901.
71. Rosten, M. (1971): Hydroxyurea. A new antimetabolite in the treatment of psoriasis. Br J Dermatol, 85, 177-181.
72. Hunter, G.A., I.J. Simmons, B.M. Thomas (1972): A clinical trial of hydroxyurea for psoriasis. Australas J Dermatol, 13, 93-99.
73. Moschella, S.L., M.A. Greenwald (1973): Psoriasis with hydroxyurea. An 18-month study of 60 patients. Arch Dermatol, 107, 363-368.
74. Layton, A.M., R.A. Sheehan-Dare, M.J. Goodfield, J.A. Cotterill (1989): Hydroxyurea in the management of therapy resistant psoriasis. Br J Dermatol, 121, 647-653.
75. Kumar, B., A. Saraswat, I. Kaur (2001): Rediscovering hydroxyurea: Its role in recalcitrant psoriasis. Int J Dermatol, 40, 530-534.
76. Leavell, U.W. Jr, I.P. Mersack, C. Smith (1973): Survey of the treatment of psoriasis with hydroxyurea. Arch Dermatol, 107, 467.
77. Stein, K.M., W.B. Shelley, R.A. Weinberg (1971): Hydroxyurea in the treatment of pustular psoriasis. Br J Dermatol, 85, 81-85.
78. Lindgren, S., O. Groth (1976): Generalized pustular psoriasis. A report on thirteen patients. Acta Derm Venereol, 56, 139-147.
79. Zackheim, H.S., M.A. Karasek, A.J. Cox Jr. (1972): Topical hydroxyurea and psoriasis. J Invest Dermatol, 58, 24-27.
80. McDonald, C.J. (1981): The uses of systemic chemotherapeutic agents in psoriasis. Pharmacol Ther, 14, 1-24.
81. Dahl, M.G., J.S. Comaish (1972): Long-term effects of hydroxyurea in psoriasis. Br Med J, 4, 585-587.
82. Parrillo, J.E., A.S. Fauci, S.M. Wolff (1977): The hypereosinophilic syndrome: Dramatic response to therapeutic intervention. Trans Assoc Am Physicians, 90, 135-144.
83. Friedhoff, F.W., M.A. Atamer, W.L. Thelmo (1978): Chronic granulocytic leukemia cutis treated with hydroxyurea. Report of a case. Chemotherapy, 24, 321-326.
84. Montefusco, E., G. Alimena, R. Gastaldi, O.A. Carlesimo, G. Valesini, F. Mandelli (1986): Unusual dermatologic toxicity of longterm therapy with hydroxyurea in chronic myelogenous leukemia. Tumori, 72, 317-321.
85. Young, H.S., B. Kirby, E.J. Stewart (2001): Aggressive, extensive, vasculitic leg ulceration associated with hydroxyurea therapy and a fatal outcome. Clin Exp Dermatol, 26, 664-667.